| Title |
Women prefer adjuvant endocrine therapy to chemotherapy for breast cancer treatment
|
|---|---|
| Published in |
Breast Cancer, November 2011
|
| DOI | 10.1007/s12282-011-0310-5 |
| Pubmed ID | |
| Authors |
Naoki Niikura, Morihiko Kimura, Takayuki Iwamoto, Naoki Hayashi, Junichi Shintoku, Yuki Saito, Yasuhiro Suzuki, Yutaka Tokuda |
| Abstract |
We attempted to determine the preferences of women regarding the benefits they considered necessary to make adjuvant therapy worthwhile, and to compare preferences for adjuvant endocrine therapy, chemotherapy, and trastuzumab therapy. We also investigated the effect of information about cost on women's treatment preferences. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 23 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 4 | 17% |
| Student > Master | 4 | 17% |
| Researcher | 3 | 13% |
| Other | 2 | 9% |
| Professor > Associate Professor | 2 | 9% |
| Other | 4 | 17% |
| Unknown | 4 | 17% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 10 | 43% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 17% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Economics, Econometrics and Finance | 1 | 4% |
| Nursing and Health Professions | 1 | 4% |
| Other | 0 | 0% |
| Unknown | 6 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 November 2011.
All research outputs
#19,495,804
of 23,975,976 outputs
Outputs from Breast Cancer
#378
of 614 outputs
Outputs of similar age
#202,200
of 246,063 outputs
Outputs of similar age from Breast Cancer
#2
of 2 outputs
Altmetric has tracked 23,975,976 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 614 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 246,063 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 2 others from the same source and published within six weeks on either side of this one.